Modality
ASO
MOA
STINGag
Target
TROP-2
Pathway
Sphingolipid
MG
Development Pipeline
Preclinical
~Aug 2015
→ ~Nov 2016
Phase 1
~Feb 2017
→ ~May 2018
Phase 2
~Aug 2018
→ ~Nov 2019
Phase 3
Feb 2020
→ May 2028
Phase 3Current
NCT04202360
2,368 pts·MG
2020-02→TBD·Not yet recruiting
NCT04231300
2,512 pts·MG
2024-03→2026-11·Not yet recruiting
NCT07395180
193 pts·MG
2020-05→2028-05·Recruiting
+1 more trial
7,424 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (3)
2026-01-133mo agoPh3 Readout· MG
2026-11-228mo awayPh3 Readout· MG
2028-05-232.1y awayPh3 Readout· MG
Trial Timeline
2020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3
P3
Not yet…
P3
Recruit…
P3
Not yet…
P3
Recruit…
Catalysts
Ph3 Readout
2026-01-13 · 3mo ago
MG
Ph3 Readout
2026-11-22 · 8mo away
MG
Ph3 Readout
2028-05-23 · 2.1y away
MG
RecruitingNot yet recruiting|StartCompletionToday
Trials (4)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04202360 | Phase 3 | MG | Not yet recr... | 2368 | BodyWt |
| NCT04231300 | Phase 3 | MG | Not yet recr... | 2512 | CfB |
| NCT07395180 | Phase 3 | MG | Recruiting | 193 | BodyWt |
| NCT07244317 | Phase 3 | MG | Recruiting | 2351 | DAS28 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| RHH-5389 | Roche | Preclinical | RET | |
| NVS-4076 | Novartis | Preclinical | TROP-2 | |
| NVS-8902 | Novartis | Preclinical | TROP-2 | |
| SNY-5894 | Sanofi | Approved | CFTR | |
| SNY-4496 | Sanofi | Phase 2/3 | CD3 | |
| SNY-5783 | Sanofi | Phase 1/2 | MET | |
| Zanumavacamten | GSK | Phase 2/3 | TROP-2 | |
| DSN-1421 | Daiichi Sankyo | Phase 3 | Nectin-4 | |
| GIL-4361 | Gilead Sciences | Preclinical | PCSK9 | |
| INC-5849 | Incyte | Phase 2 | PCSK9 |